Your browser doesn't support javascript.
loading
Florbetapir imaging in cerebral amyloid angiopathy-related hemorrhages.
Raposo, Nicolas; Planton, Mélanie; Péran, Patrice; Payoux, Pierre; Bonneville, Fabrice; Lyoubi, Aicha; Albucher, Jean François; Acket, Blandine; Salabert, Anne Sophie; Olivot, Jean Marc; Hitzel, Anne; Chollet, François; Pariente, Jérémie.
Afiliación
  • Raposo N; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Planton M; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Péran P; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Payoux P; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Bonneville F; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Lyoubi A; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Albucher JF; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Acket B; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Salabert AS; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Olivot JM; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Hitzel A; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Chollet F; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
  • Pariente J; From the Neurology Department (N.R., M.P., A.L., J.F.A., B.A., J.M.O., F.C., J.P.), Nuclear Medicine Department (P. Payoux, A.S.S., A.H.), and Neuroradiology Department (F.B.), Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse; and Toulouse NeuroImaging Center (N.R., M.P., P.
Neurology ; 89(7): 697-704, 2017 Aug 15.
Article en En | MEDLINE | ID: mdl-28724587
ABSTRACT

OBJECTIVE:

To assess whether 18F-florbetapir, a PET amyloid tracer, could bind vascular amyloid in cerebral amyloid angiopathy (CAA) by comparing cortical florbetapir retention during the acute phase between patients with CAA-related lobar intracerebral hemorrhage (ICH) and patients with hypertension-related deep ICH.

METHODS:

Patients with acute CAA-related lobar ICH were prospectively enrolled and compared with patients with deep ICH. 18F-florbetapir PET, brain MRI, and APOE genotype were obtained for all participants. Cortical florbetapir standard uptake value ratio (SUVr) was calculated with the whole cerebellum used as a reference. Patients with CAA and those with deep ICH were compared for mean cortical florbetapir SUVr values.

RESULTS:

Fifteen patients with acute lobar ICH fulfilling the modified Boston criteria for probable CAA (mean age = 67 ± 12 years) and 18 patients with acute deep ICH (mean age = 63 ± 11 years) were enrolled. Mean global cortical florbetapir SUVr was significantly higher among patients with CAA-related ICH than among patients with deep ICH (1.27 ± 0.12 vs 1.12 ± 0.12, p = 0.001). Cortical florbetapir SUVr differentiated patients with CAA-ICH from those with deep ICH (area under the curve = 0.811; 95% confidence interval [CI] 0.642-0.980) with a sensitivity of 0.733 (95% CI 0.475-0.893) and a specificity of 0.833 (95% CI 0.598-0.948).

CONCLUSIONS:

Cortical florbetapir uptake is increased in patients with CAA-related ICH relative to those with deep ICH. Although 18F-florbetapir PET can label vascular ß-amyloid and might serve as an outcome marker in future clinical trials, its diagnostic value in acute CAA-related ICH seems limited in clinical practice.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Corteza Cerebral / Hemorragia Cerebral / Péptidos beta-Amiloides / Angiopatía Amiloide Cerebral / Tomografía de Emisión de Positrones / Glicoles de Etileno / Compuestos de Anilina Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Neurology Año: 2017 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Corteza Cerebral / Hemorragia Cerebral / Péptidos beta-Amiloides / Angiopatía Amiloide Cerebral / Tomografía de Emisión de Positrones / Glicoles de Etileno / Compuestos de Anilina Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Neurology Año: 2017 Tipo del documento: Article